Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653625 · ClinicalTrials.gov registry record · Phase 2
PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis
A Phase 2 study, sponsored by Tobira Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02653625 is a Phase 2 study that has completed, run by Tobira Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT02653625, a Phase 2 study, has completed, sponsored by Tobira Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.
Interventions
- DRUG Cenicriviroc 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-03-14 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02653625
The ClinicalTrials.gov registry entry for NCT02653625 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tobira Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cenicriviroc 150 mg is the first listed.
NCT02653625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02653625 about?
NCT02653625 is a clinical study titled "PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis". This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.
What is the current status of trial NCT02653625?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-03-14. Estimated completion is 2017-08-31.
What interventions are being tested in trial NCT02653625?
The interventions under investigation include: Cenicriviroc 150 mg (DRUG).
Who is sponsoring clinical trial NCT02653625?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.